Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 3101 to 3150 of 4138 results for patient

  1. Durvalumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6146]

    Awaiting development Reference number: GID-TA11222 Expected publication date: TBC

  2. Ex-situ machine perfusion devices for extracorporeal preservation of lungs for transplant

    In development Reference number: GID-HTE10084 Expected publication date: TBC

  3. Digital technologies delivering CBT for insomnia and insomnia symptoms (provisional title)

    In development Reference number: GID-HTE10068 Expected publication date: TBC

  4. Cryotherapy as a primary treatment for prostate cancer (IPG145)

    Evidence-based recommendations on cryotherapy as a primary treatment for prostate cancer. This involves using cold temperature to freeze and destroy cancer tissue as a first treatment for cancer that hasn't spread far from the prostate.

  5. Laser-assisted cerebral vascular anastomosis without temporary arterial occlusion (IPG252)

    Evidence-based recommendations on laser-assisted cerebral vascular anastomosis without temporary arterial occlusion. This involves using a special laser device to create a bypass without the need to temporarily interrupt the blood flow to the brain.

  6. Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusion (TA1004)

    Evidence-based recommendations on faricimab (Vabysmo) for treating visual impairment caused by macular oedema after retinal vein occlusion in adults.

  7. Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA1007)

    Evidence-based recommendations on rucaparib (Rubraca) for the maintenance treatment of relapsed platinum-sensitive high-grade epithelial, ovarian, fallopian tube or primary peritoneal cancer that has completely or partially responded to platinum-based chemotherapy in adults.

  8. Risankizumab for treating moderately to severely active ulcerative colitis (TA998)

    Evidence-based recommendations on risankizumab (Skyrizi) for treating moderately to severely active ulcerative colitis in adults.

  9. Liraglutide for managing overweight and obesity (TA664)

    Evidence-based recommendations on liraglutide (Saxenda) for managing overweight and obesity alongside a reduced-calorie diet and increased physical activity in adults.

  10. Betula verrucosa for treating moderate to severe allergic rhinitis or conjunctivitis caused by tree pollen (TA1087)

    Evidence-based recommendations on betula verrucosa (Itulazax 12 SQ Bet) for treating moderate to severe allergic rhinitis or conjunctivitis caused by pollen from trees in the birch allergy group in adults.

  11. Laparoscopic retroperitoneal lymph node dissection for testicular cancer (IPG158)

    Evidence-based recommendations on laparoscopic retroperitoneal lymph node dissection for testicular cancer. This involves using smaller openings in the skin (keyhole surgery) to remove the lymph nodes.

  12. Photodynamic therapy for early-stage oesophageal cancer (IPG200)

    Evidence-based recommendations on photodynamic therapy for early-stage oesophageal cancer. This involves injecting a photosensitising agent into the tumour which is then activated by a light to destroy the tumour cells.

  13. Sipavibart for preventing COVID-19 [ID6282]

    In development Reference number: GID-TA11352 Expected publication date: TBC

  14. Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B (TA96)

    Evidence-based recommendations on adefovir dipivoxil (Hepsera) and peginterferon alfa-2a (Pegasys) for treating chronic hepatitis B in adults.

  15. Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 2 therapies [ID5108]

    Awaiting development Reference number: GID-TA11018 Expected publication date: TBC

  16. Surgical mesh for ventral hernias

    In development Reference number: GID-HTE10080 Expected publication date: TBC

  17. Digital hearing aids (Provisional title)

    In development Reference number: GID-HTE10079 Expected publication date: TBC

  18. Technologies to support the rapid diagnosis of endometriosis (provisional title)

    In development Reference number: GID-HTE10082 Expected publication date: TBC

  19. Depemokimab for treating severe eosinophilic asthma in people 12 years and over [ID6447]

    In development Reference number: GID-TA11553 Expected publication date: TBC

  20. Thrombin injections for pseudoaneurysms (IPG60)

    Evidence-based recommendations on thrombin injections for pseudoaneurysms. This involves injecting thrombin into the pseudoaneurysm. The aim is to form a small clot to plug the ‘hole’ in the artery.

  21. ProciseDx point-of-care platform for inflammatory bowel disease (MIB302)

    NICE has developed a medtech innovation briefing (MIB) on ProciseDx point-of-care platform for inflammatory bowel disease .

  22. Stent placement for vena caval obstruction (IPG79)

    Evidence-based recommendations on stent placement for vena caval obstruction. This involves using a catheter to position a stent, which may be self-expanding or balloon-dilated, across the area of narrowing to relieve it.

  23. Cryotherapy for malignant endobronchial obstruction (IPG142)

    Evidence-based recommendations on cryotherapy for malignant endobronchial obstruction. This involves using cold temperatures to destroy the cancer tissue that’s causing a blockage.

  24. Brachytherapy as the sole method of adjuvant radiotherapy for breast cancer after local excision (IPG268)

    Evidence-based recommendations on brachytherapy as the sole method of adjuvant radiotherapy for breast cancer after local excision. This involves inserting radioactive sources into the space in the breast where tissue has been removed to minimise the chances of the cancer coming back.

  25. Facial erythema of rosacea: brimonidine tartrate gel (ESNM43)

    Summary of the evidence on brimonidine tartrate gel for treating facial erythema of rosacea to inform local NHS planning and decision-making

  26. High-throughput non-invasive prenatal testing for fetal RHD genotype (HTG420)

    Evidence-based recommendations on high-throughput non-invasive prenatal testing (NIPT) for fetal RHD genotype.

  27. Pridopidine for treating Huntington's disease [ID6525]

    Awaiting development Reference number: GID-TA11637 Expected publication date: TBC

  28. Delandistrogene moxeparvovec for treating Duchenne muscular dystrophy in children 4 to 7 years ID3897

    In development Reference number: GID-TA11437 Expected publication date: TBC

  29. Linerixibat for treating pruritus in people with primary biliary cholangitis [ID6265]

    In development Reference number: GID-TA11307 Expected publication date:  06 January 2027

  30. Mental health problems in people with learning disabilities: prevention, assessment and management (NG54)

    This guideline covers preventing, assessing and managing mental health problems in people with learning disabilities in all settings (including health, social care, education, and forensic and criminal justice). It aims to improve assessment and support for mental health conditions, and help people with learning disabilities and their families and carers to be involved in their care.

  31. Preterm labour and birth (NG25)

    This guideline covers the care of women with a singleton pregnancy at increased risk of, or with symptoms and signs of, preterm labour (before 37 weeks), and women with a singleton pregnancy having a planned preterm birth. It aims to reduce the risks of preterm birth for the baby and describes treatments to prevent or delay early labour and birth.

  32. Chronic heart failure in adults: diagnosis and management (NG106)

    This guideline covers diagnosing and managing chronic heart failure in people aged 18 and over. It aims to improve diagnosis and treatment to increase the length and quality of life for people with heart failure.

  33. Laparoscopic nephrolithotomy and pyelolithotomy (IPG212)

    Evidence-based recommendations on laparoscopic nephrolithotomy and pyelolithotomy. This involves inserting a tube through small cuts in the abdomen (keyhole surgery) to remove the kidney stones.

  34. Mirikizumab for treating moderately to severely active ulcerative colitis (TA925)

    Evidence-based recommendations on mirikizumab (Omvoh) for treating moderately to severely active ulcerative colitis in adults.

  35. Endobronchial ultrasound-guided transbronchial needle aspiration for mediastinal masses (IPG254)

    Evidence-based recommendations on endobronchial ultrasound-guided transbronchial needle aspiration for mediastinal masses. This involves inserting a thin tube through the mouth into the lungs to take samples for examination.

  36. Twin and triplet pregnancy (NG137)

    This guideline covers care for pregnant women and pregnant people with a twin or triplet pregnancy in addition to routine care during pregnancy and labour. It aims to reduce the risk of complications and improve outcomes.

  37. Complete cytoreduction for pseudomyxoma peritonei (Sugarbaker technique) (IPG56)

    Evidence-based recommendations on complete cytoreduction for pseudomyxoma peritonei (Sugarbaker technique). This involves complete surgical tumour removal with intraoperative heated chemotherapy, and is followed by postoperative intraperitoneal chemotherapy.

  38. Endoaortic balloon occlusion for cardiac surgery (IPG261)

    Evidence-based recommendations on endoaortic balloon occlusion for cardiac surgery. This involves inserting a tube with a balloon attached into the aorta and filling it with saline to block blood flowing from the heart so that surgery can be done.

  39. Ultrasound-guided regional nerve block (IPG285)

    Evidence-based recommendations on ultrasound-guided regional nerve block. This involves using ultrasound guidance to position needles that deliver local anaesthetic in the correct place next to the nerves.

  40. Leriglitazone for treating andrenoleukodystrophy [ID3903]

    In development Reference number: GID-TA11445 Expected publication date: TBC

  41. Durvalumab with tremelimumab for treating limited-stage small-cell lung cancer after chemoradiation [ID5097]

    Awaiting development Reference number: GID-TA11214 Expected publication date: TBC

  42. Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent [ID6207]

    In development Reference number: GID-TA11235 Expected publication date: TBC

  43. Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver: draft scope consultation

    We are listening to your views on this Interventional procedures guidance. Comments close 19 December 2025.

  44. Capsule sponge tests for surveillance of Barrett's oesophagus (provisional title)

    In development Reference number: GID-HTE10070 Expected publication date: TBC

  45. Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver

    In development Reference number: GID-IPG10448 Expected publication date: TBC

  46. Middle meningeal artery embolisation for chronic subdural haematomas

    In development Reference number: GID-IPG10440 Expected publication date: TBC

  47. Middle meningeal artery embolisation for chronic subdural haematomas: draft scope consultation

    We are listening to your views on this Interventional procedures guidance. Comments close 7 January 2026.

  48. Inebilizumab for treating AQP4-IgG-seropositive neuromyelitis optica spectrum disorders [ID6430]

    Awaiting development Reference number: GID-TA11530 Expected publication date: TBC

  49. Cryotherapy for recurrent prostate cancer (IPG119)

    Evidence-based recommendations on cryotherapy for treating recurrent prostate cancer. This involves putting special needles or probes into the prostate and using Argon gas to freeze and destroy the cancerous prostate tissue.